HSBC Downgrades Amgen Stock to Hold on Valuation Concerns

HSBC downgraded Amgen (NASDAQ:AMGN) to Hold from Buy and lowered its price target to $425 from $445, pointing to valuation limits following a recent share re-rating. While the bank maintains its long-term growth outlook, the downward adjustment reflects a near-term ceiling as shares approach fair value.

"The shares have re-rated on strong execution and positive estimate revisions, leaving the stock trading around fair value and close to the firm's target price," said Morten Herholdt, analyst at HSBC, in a note regarding the rating change.

Pipeline Timelines and Valuation Pressures

The revision follows a period of strong operational performance that pushed Amgen shares higher. According to an Investing.com report, the bank adjusted its target to $425 from $445 after concluding that the current market price already accounts for near-term catalysts.

Key pipeline value drivers, including experimental treatments such as MariTide for obesity, Olpasiran for cardiovascular disease, and Imdelltra for small cell lung cancer, are back-ended to late 2027. This timeline leaves a gap in immediate catalysts that could drive further stock appreciation in the short term.

Navigating the Patent Cliff

Despite the downgrade to a Hold rating, HSBC's long-term investment thesis for the biotechnology company remains unchanged. The firm anticipates that Amgen will successfully navigate upcoming patent expirations on older blockbuster drugs by relying on its rare disease portfolio, recent product launches, and an expanding biosimilar business.

At the same time, HSBC Holdings PLC-Spons ADR (HSBC) shares traded in the broader market, closing a recent session at $105.30, up 1.54% from its previous close of $103.70, according to Finnhub market data.

What Is at Stake for Biotechnology Investors

The rating change underscores the tension between long-term biopharmaceutical growth potential and near-term market valuation multiples. As major drug developers manage looming patent cliffs while funding costly late-stage clinical trials, analysts are increasingly scrutinizing whether current equity valuations leave adequate room for upside before key pipeline readouts arrive.

Market Response and Trading Range

The adjustment by HSBC highlights how execution-driven estimate revisions can compress prospective returns even for well-positioned industry leaders. Investors tracking Amgen are weighing the balance between foundational drug franchises and the delayed payoff of pipeline assets expected to mature around late 2027.